

**PROGRAM** 

24 June 2023 Montréal Canada 28

## HORIBA Medical



# SCIENTIFIC PRESENTATION



### Saturday, June 24th, 2023

HORIBA Medical Supported Symposia – 11:30 – 12:45 – Room: 516 Current Advanced in Deficient Factors, Heparin Testing and HIL

#### **Presenters:**



Dr. Emmanuelle JEANPIERRE
Hematology Transfusion Institute of Lille University Hospital - France
Sensitivity of three new Prothrombin Time reagent to extrinsic pathway factor deficiencies.

Prothrombin time is widely used for monitoring vitamin K antagonist-based anticoagulant therapy but also as a screening test for extrinsic factor deficiency (congenital or acquired).

The sensitivity of three new reagents (Yumizen G PT 5, Yumizen G PT Reco, and Yumizen G PT Liq) was compared with that of two other reagents available in the laboratory (STA-Neo R and STA-NeoPTimal).

For all five reagents, the analyses were performed on Yumizen G1550 and STAGO STA-R Max 2 to compare the performance of each reagent/instrument combination.



Mr. Kevin HORNER

Department of Coagulation, Sheffield Haemophilia and Thrombosis Centre - UK Evaluation of the new Preanalytical HIL (Haemolysis, Icterus & Lipemia) on HORIBA Medical analysers.

Haemolysis, Icterus and Lipemia have been reported to cause interference in haemostasis assays, which may unpredictably vary between different reagent analyser combinations.

The ability to determine each indice is a mainstay for determining sample quality. We report on findings of our evaluation looking at both spurious and native samples.



Pr. Corinne FRERE

Biological Hematology Department of Pitié-Salpêtrière University Hospital – France Performance evaluation of the ACTICHROME Heparin Anti-Xa™ assay for the quantitative determination of UFH and LMWH plasma concentrations.


The ACTICHROME Heparin Anti-Xa™ assay (HORIBA Medical) is a newly launched, specific, easy to use and fully automated chromogenic assay for the quantitative determination of plasma concentrations of unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH).

We report on findings of our evaluation of this new reagent.



**Moderator:** 

**Dr. Steve KITCHEN**Lead Clinical Scientist,
Department of Coagulation, Sheffield Haemophilia and Thrombosis
Centre - UK





#### **REGISTER HERE**

https://www.isth2023.org/register









